Want to see WST full AI Analyst Report?
Net Sales by Segment
Shows how much revenue each part of the business contributes, revealing which products or markets are driving growth and where the company may be dependent on a few segments or customers. Useful for spotting concentration risk and understanding whether West’s revenue mix is shifting toward higher-growth areas like advanced delivery systems or stable component sales.Proprietary Products are the engine — recent quarters show accelerating organic growth and a mix shift toward HVP/GLP‑1 and biologics, which helps explain the company’s margin expansion and underpins the guidance raise; Annex‑1 conversions and SmartDose contributed to the uplift. West Vantage is steady but lower-growth, with near-term margin drag from the Dublin ramp. Watch H2 cadence: a CGM contract roll‑off and SmartDose transaction timing could temper second‑half sales despite strong full‑year momentum.
Date | Proprietary Products | West Vantage |
|---|---|---|
Jun 30, 2026 | $722.60M | $149.70M |
Mar 31, 2026 | $694.30M | $150.60M |
Dec 31, 2025 | $661.80M | $143.20M |
Sep 30, 2025 | $647.50M | $157.10M |
Jun 30, 2025 | $619.80M | $146.70M |
Mar 31, 2025 | $563.00M | $135.00M |
Dec 31, 2024 | $613.90M | $134.90M |
Sep 30, 2024 | $601.40M | $145.50M |
Jun 30, 2024 | $559.70M | $142.40M |
Mar 31, 2024 | $559.50M | $135.90M |